HCA Healthcare stock (NYSE: HCA) sinks 7.6% as uninsured costs force a 2026 reset

HCA Healthcare, Inc. (NYSE: HCA) operates hospitals, surgical facilities, emergency centres and other healthcare services across the United States and the United Kingdom. Its shares fell 7.6% to US$361.04 by 12:55 p.m. ET on July 14, reducing the company’s market capitalisation to approximately US$81.8 billion. The sell-off followed preliminary second-quarter results that combined higher revenue and patient admissions with weaker margins and a reduced profit outlook. HCA’s July 24 earnings report is now the next test of whether the deterioration in payer mix represents a manageable 2026 adjustment or a more persistent earnings problem.

Why did HCA Healthcare stock fall despite stronger second-quarter revenue and earnings?

HCA expects second-quarter revenue of approximately US$20.23 billion, up 8.7% from US$18.61 billion a year earlier. Net income attributable to the company is expected to reach US$1.70 billion, compared with US$1.65 billion in the corresponding period.

Diluted earnings per share increased 11.6% from US$6.83 to US$7.62. On an adjusted basis, excluding gains and losses from facility sales, earnings per share are expected to rise from US$6.84 to US$7.59.

The stronger earnings-per-share growth partly reflects HCA’s reduced share count. The diluted number of shares used in the calculation fell from 241.9 million to 222.8 million, a reduction of almost 8%. Net income increased only 2.8%, meaning share repurchases made a meaningful contribution to the reported per-share growth.

The profitability trend was less favourable. Adjusted EBITDA increased 4.6% to approximately US$4.03 billion, considerably slower than revenue. HCA’s adjusted EBITDA margin consequently declined from 20.7% to 19.9%. That 0.8 percentage-point contraction helps explain why investors looked beyond the headline revenue and EPS growth.

How does the US$400 million uninsured-patient impact change HCA’s 2026 outlook?

HCA said the second-quarter payer mix deteriorated because of an increase in uninsured patients, primarily involving people who had lost coverage through health insurance exchanges. The company estimates that this shift reduced income before tax by approximately US$400 million.

The estimate includes an additional US$75 million adjustment to the company’s previous assessment of the first-quarter exchange impact. This indicates that the financial effect is not confined to a single reporting period and that HCA’s earlier assumptions did not fully capture the eventual pressure.

For the full year, management now expects health insurance exchange changes to reduce pre-tax income by US$1.0 billion to US$1.2 billion. The previous estimate was US$600 million to US$900 million. At the midpoint, the expected impact has worsened by approximately US$350 million.

The problem is not simply whether more patients are visiting HCA facilities. Hospitals continue to incur staffing, pharmaceutical, diagnostic and facility costs when treating uninsured patients, especially through emergency departments. A shift from commercially insured activity towards uninsured care can therefore produce higher patient volumes without a corresponding increase in profit.

HCA recognised approximately US$400 million of incremental second-quarter benefit from Medicaid Supplemental Payment Programs, primarily related to a Florida state-directed payment programme. That benefit provided a material offset, but it should not automatically be treated as a recurring answer to future payer-mix pressure. The timing and value of supplemental payments remain dependent on programme approvals and reimbursement arrangements.

What do rising hospital admissions and falling surgical volumes reveal about HCA’s margins?

Same-facility admissions increased 2.5% in the second quarter, while equivalent admissions rose 2.7%. Same-facility emergency-room visits grew 3.6%.

These figures show that demand across HCA’s hospital network remains healthy. They also represent an improvement from the first quarter, when same-facility admissions rose 0.9%, equivalent admissions increased 1.3% and emergency-room visits grew only 0.3%.

The weaker indicator is surgical activity. Same-facility inpatient surgeries declined 2.3%, while outpatient surgeries fell 3.4%. These declines were larger than in the first quarter, when inpatient and outpatient surgeries decreased 0.3% and 1.7%, respectively.

Surgical procedures can carry more attractive economics than general inpatient or emergency activity. Fewer elective procedures, combined with higher uninsured emergency volumes, can weaken the service mix even as total admissions rise. HCA therefore needs more than patient growth. It needs stabilisation in insured volumes and higher-value procedures if it is to recover the margin lost during the first half.

How has HCA Healthcare’s guidance cut changed the stock’s valuation after the sell-off?

HCA narrowed its 2026 revenue forecast from US$76.5 billion to US$80.0 billion to a new range of US$77.0 billion to US$79.5 billion. The midpoint remains unchanged at US$78.25 billion.

The unchanged revenue midpoint is important because it confirms that management is not forecasting a major demand shortfall. Instead, the company expects less of that revenue to reach shareholders as profit.

Net income attributable to HCA is now expected to range from US$6.3 billion to US$6.7 billion, down from US$6.50 billion to US$7.04 billion. The midpoint has fallen approximately 3.9%. Adjusted EBITDA guidance was reduced from US$15.55 billion to US$16.45 billion to US$15.4 billion to US$16.1 billion.

Diluted EPS guidance fell from US$29.10 to US$31.50 to US$28.70 to US$30.50. Its midpoint declined from US$30.30 to US$29.60.

At US$361.04, HCA shares were down approximately 14.7% from their July 7 close of US$423.11. The stock had fallen about 6.8% from its June 12 close of US$387.18 and was 5.1% below its closing price one year earlier.

The current price sits within a 52-week range of US$330.00 to US$556.52. HCA is trading approximately 35% below the high but only 9% above the low. Based on trailing EPS of approximately US$29.03, the shares trade at about 12.4 times earnings. They are valued at roughly 12.2 times the midpoint of revised 2026 EPS guidance.

That multiple may look modest compared with the valuation investors accepted when HCA traded above US$500. However, the discount reflects greater uncertainty around reimbursement, healthcare policy and margins. The valuation becomes more compelling only if the revised guidance captures most of the payer-mix deterioration.

Can HCA Healthcare’s cash flow support its US$48 billion debt load and capital spending?

HCA reported US$940 million of cash and cash equivalents at March 31 against total debt of US$48.02 billion. Its debt load is significant and makes consistent earnings and operating cash flow important.

The company generated US$2.01 billion of operating cash flow during the first quarter, up 22% from US$1.65 billion a year earlier. Capital expenditure totalled US$1.12 billion, leaving approximately US$895 million after capital spending and before other investing or financing requirements.

HCA continues to forecast 2026 capital expenditure of US$5.0 billion to US$5.5 billion, excluding acquisitions. These investments support capacity expansion, facility maintenance and the digitisation of its healthcare networks. They also mean that not all operating cash flow is available for debt reduction, dividends or share repurchases.

The current figures do not suggest an immediate funding crisis. HCA remains profitable and produces substantial cash flow. Nevertheless, high debt and capital requirements reduce the margin for error if uninsured volumes continue increasing or reimbursement changes weaken earnings further.

What evidence on July 24 would strengthen or weaken the HCA Healthcare investment case?

HCA’s July 24 earnings report and conference call must provide more detail on the timing and geographic concentration of the US$400 million payer-mix impact. Investors need to know whether uninsured volumes stabilised during the quarter or continued worsening into June.

The company also needs to explain the decline in surgical procedures. A recovery in elective and commercially insured activity would improve the service mix. Continued surgical weakness would indicate that the margin problem extends beyond temporary reimbursement timing.

Evidence that payer mix is stabilising, expense controls remain effective and surgical volumes are recovering would strengthen the case that the sell-off has reset the valuation too aggressively. Consistent operating cash flow would provide additional support, particularly given HCA’s debt and capital expenditure commitments.

The principal downside risks are further losses of insurance coverage, continued weakness in higher-value surgical procedures and a larger-than-expected effect from healthcare policy changes. Another reduction in guidance, weaker cash conversion or evidence that supplemental payments merely masked deeper operating pressure would weaken the thesis.

HCA remains a highly profitable hospital operator with rising admissions, considerable scale and strong cash generation. What has changed is the quality of its growth: more patients are not producing proportionate earnings because the payer and service mix has deteriorated. The US$361 share price offers a lower valuation, but the July 24 update must show that management’s revised outlook adequately captures the pressure.

What are the key takeaways for HCA Healthcare investors after the 2026 guidance reset?

• HCA Healthcare shares fell 7.6% after higher uninsured volumes forced management to reduce its 2026 profit outlook.
• Preliminary second-quarter revenue increased 8.7% to US$20.23 billion, but the adjusted EBITDA margin declined from 20.7% to 19.9%.
• HCA estimates that the payer-mix deterioration reduced second-quarter pre-tax income by approximately US$400 million.
• Same-facility admissions rose 2.5%, but inpatient and outpatient surgeries declined 2.3% and 3.4%, respectively.
• The stock is down approximately 14.7% over five trading days and trades at about 12.2 times the midpoint of revised 2026 EPS guidance.
• A stabilising payer mix, recovering surgical volumes and resilient cash flow would support the upside scenario.
• The July 24 earnings update must provide evidence that uninsured-care costs and margin pressure have been fully reflected in guidance.